From Podium to Practice: HIV Management in Developed Countries
Source: 2009 IAS Conference on HIV Pathogenesis, Treatment and Prevention

Conference Program

 

Expert Analysis

Andrew Carr, MBBS, MD, FRACP, FRCP; Anton L. Pozniak, MD, FRCP; and Kimberly Y. Smith, MD, MPH, discuss key studies pertaining to the management of HIV infection in developed nations presented at the 2009 International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention with a focus on the implications of those findings for clinical practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the latest clinical findings on potential associations between use of antiretroviral agents and cardiovascular disease risk
  • Describe recent data on the relative efficacy of antiretroviral therapy in treatment-experienced women vs men
  • Discuss new results from clinical trials investigating drug class-sparing regimens and other treatment simplification strategies
  • Cite the most recent data on the safety and efficacy of new antiretroviral agents
  • Articulate new findings from studies evaluating prevalence and risk factors for bone mineral density loss and vitamin D deficiency among HIV-infected patients

Topics covered include:

  • Abacavir Exposure, Chronic Kidney Disease, and Risk of Cardiovascular Disease Risk in a VA Cohort
  • BICOMBO Substudy: Abacavir and Tenofovir Exposure and Biomarkers of Cardiovascular Dysfunction
  • Case-Control Study of Quebec’s Public Health Insurance Database: NRTI or PI Exposure and Risk of Acute MI
  • GRACE: Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Women vs Men
  • FOTO: 5-Days-On, 2-Days-Off vs Standard Efavirenz, Tenofovir, Emtricitabine Dosing
  • Switch to Raltegravir Plus Unboosted Atazanavir in Treatment-Experienced Patients
  • ARIES: Simplifying First-line Atazanavir/Ritonavir to Atazanavir Following Virologic Suppression
  • Switch From Stable HAART to Darunavir/Ritonavir Monotherapy
  • Once-Daily vs Twice-Daily Lopinavir/Ritonavir Plus 2 NRTIs in Treatment-Experienced Patients
  • MERIT-ES: Maraviroc vs Efavirenz at Week 96 in Treatment-Naive Patients
  • ARTEN: First-line Atazanavir/Ritonavir vs Nevirapine
  • Dose-Ranging Study of Novel Integrase Inhibitor, S/GSK1349572, in HIV-Infected Patients
  • SPAR Substudy: Bone Mineral Density Loss With NRTI- vs PI-Sparing Regimens
  • Risk Factors for Vitamin D Deficiency Among HIV-Infected Patients in a United Kingdom Cohort
  • ESPRIT, SILCAAT, and STALWART: Clinical Utility of IL-2 Therapy in HIV-Infected Patients
 

Faculty

  		•
    Andrew Carr
    MBBS, MD, FRACP
    Anton L. Pozniak
    MD, FRCP
    Kimberly Y. Smith
    MD, MPH

Credit Information

  • Release Date:
    October 09, 2009
  • Expiration Date:
    October 08, 2010
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit™
  • Registered Nurses:
    1.0 Nursing contact hour
  • Pharmacists:
    1.0 contact hour (0.1 CEUs)
Jointly sponsored by USF Health and Clinical Care Options, LLC.
 
 
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Related Content

  • Does CNS Penetration Matter When Selecting Antiretroviral Regimens?

    Eric S. Daar MD - 4/2/2013    7 comments / Last Comment: 5/15/2013
    Antiretroviral agents differ substantially in their ability to penetrate the CNS. Should this influence selection of initial ART in patients with HIV-associated neurocognitive disease?
    See all Thoughts >>
    Hide All >>

  • Applying OPTIONS: When Can Our Treatment-Experienced Patients Discontinue NRTIs?

    Andrew R. Zolopa MD - 5/8/2013    
    The OPTIONS trial suggested that some treatment-experienced patients may not need NRTIs, but how do you translate this to clinical practice?
    See all Thoughts >>
    Hide All >>

  • Then and Now: The Evolution of Treatment in HIV

    David A. Wohl MD - 3/14/2013    1 comment / Last Comment: 4/22/2013
    Remembering the initial days of the HIV epidemic and care highlights how far we have come in treatment options and approaches to care in patients infected with HIV.
    See all Thoughts >>
    Hide All >>

  • Would You Switch ART in This Hospitalized Patient With an Acute Cardiovascular Event?

    Eric S. Daar MD - 4/11/2013    3 comments / Last Comment: 4/25/2013
    How would you manage antiretroviral therapy in this patient on an abacavir-containing regimen?
    See all Thoughts >>
    Hide All >>

  • How Would You Manage a Newly Pregnant Woman With Multiple Recent HIV Exposures?

    W. David Hardy MD - 3/7/2013    4 comments / Last Comment: 4/22/2013
    How would you manage this patient who is only 2 weeks pregnant and realizes that she has been repeatedly exposed to HIV while attempting conception with her spouse?
    See all Thoughts >>
    Hide All >>